181 related articles for article (PubMed ID: 15501422)
1. Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine.
Ghelardini C; Galeotti N; Grazioli I; Uslenghi C
J Pain; 2004 Oct; 5(8):413-9. PubMed ID: 15501422
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study.
Sandrini G; Cerbo R; Del Bene E; Ferrari A; Genco S; Grazioli I; Martelletti P; Nappi G; Pinessi L; Sarchielli P; Tamburro P; Uslenghi C; Zanchin G
Int J Clin Pract; 2007 Aug; 61(8):1256-69. PubMed ID: 17627707
[TBL] [Abstract][Full Text] [Related]
3. The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.
Ghelardini C; Galeotti N; Vivoli E; Grazioli I; Uslenghi C
J Headache Pain; 2009 Dec; 10(6):435-40. PubMed ID: 19756945
[TBL] [Abstract][Full Text] [Related]
4. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
Jakubowski M; Levy D; Goor-Aryeh I; Collins B; Bajwa Z; Burstein R
Headache; 2005; 45(7):850-61. PubMed ID: 15985101
[TBL] [Abstract][Full Text] [Related]
5. Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in in vivo models of migraine.
Galeotti N; Ghelardini C; Grazioli I; Uslenghi C
Pharmacol Res; 2002 Sep; 46(3):245-50. PubMed ID: 12220967
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.
Di Monda V; Nicolodi M; Aloisio A; Del Bianco P; Fonzari M; Grazioli I; Uslenghi C; Vecchiet L; Sicuteri F
Headache; 2003 Sep; 43(8):835-44. PubMed ID: 12940804
[TBL] [Abstract][Full Text] [Related]
7. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
Burstein R; Jakubowski M
Ann Neurol; 2004 Jan; 55(1):27-36. PubMed ID: 14705109
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.
Linde M; Mellberg A; Dahlöf C
Cephalalgia; 2006 Feb; 26(2):113-21. PubMed ID: 16426264
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.
Hoy SM; Scott LJ
CNS Drugs; 2011 Apr; 25(4):343-58. PubMed ID: 21425885
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Kostic MA; Gutierrez FJ; Rieg TS; Moore TS; Gendron RT
Ann Emerg Med; 2010 Jul; 56(1):1-6. PubMed ID: 20045576
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A; Gennings C; Cady R
Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
[TBL] [Abstract][Full Text] [Related]
12. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists.
Levy D; Jakubowski M; Burstein R
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4274-9. PubMed ID: 15016917
[TBL] [Abstract][Full Text] [Related]
13. Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans.
Peng KP; Jürgens T; Basedau H; Ortlieb L; May A
Eur J Pain; 2022 Nov; 26(10):2152-2161. PubMed ID: 36001070
[TBL] [Abstract][Full Text] [Related]
14. Clarification of developing and established clinical allodynia and pain-free outcomes.
Landy SH; McGinnis JE; McDonald SA
Headache; 2007 Feb; 47(2):247-52. PubMed ID: 17300364
[TBL] [Abstract][Full Text] [Related]
15. Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention.
Landy S; Hoagland R; Hoagland NA
Headache; 2012 Jan; 52(1):133-9. PubMed ID: 21883200
[TBL] [Abstract][Full Text] [Related]
16. Acute migraine therapy: recent evidence from randomized comparative trials.
Mett A; Tfelt-Hansen P
Curr Opin Neurol; 2008 Jun; 21(3):331-7. PubMed ID: 18451718
[TBL] [Abstract][Full Text] [Related]
17. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Hoskin KL; Goadsby PJ
Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
[TBL] [Abstract][Full Text] [Related]
18. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.
Akerman S; Karsan N; Bose P; Hoffmann JR; Holland PR; Romero-Reyes M; Goadsby PJ
Brain; 2019 Jan; 142(1):103-119. PubMed ID: 30596910
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group.
Pini LA; Fabbri L; Cavazzuti L
Int J Clin Pharmacol Res; 1999; 19(2):57-64. PubMed ID: 10669900
[TBL] [Abstract][Full Text] [Related]
20. A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Kopruszinski CM; Navratilova E; Swiokla J; Dodick DW; Chessell IP; Porreca F
Cephalalgia; 2021 Mar; 41(3):305-317. PubMed ID: 32985222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
